In 2020, the global peripheral vascular device market size was valued at $11.9 billion, with over 16 million yearly peripheral vascular procedures performed. The market size is expected to increase at a compound annual growth rate (CAGR) of 5.2% to reach $16.9 billion in 2026. Throughout this medical market research, we analyzed 113 peripheral vascular

In 2020, the European peripheral vascular device market size was valued at about €1.3 billion, with over 1.15 million peripheral vascular procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 2.9% to reach €1.6 billion in 2026. Throughout this medical market research, we analyzed 65

The full report suite on the U.S. market for peripheral vascular devices includes peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloon catheters, drug-coated balloons (DCBs), atherectomy devices, intravascular lithotripsy, chronic total occlusion (CTO) devices, surgical grafts, stent grafts, embolic protection devices (EPDs), peripheral thrombus management devices, inferior vena cava filters (IVCFs) and retrieval devices, carotid shunts, transcarotid arterial revascularization (TCAR) flow reversal systems and stents, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths, vascular closure devices (VCDs), transcatheter embolization devices and peripheral IVUS catheters.

The global peripheral chronic total occlusion (CTO) device market is expected to increase over the forecast period to reach $258.2 million by 2026. This global market research on chronic total occlusion (CTO) devices spans over 70 countries and includes re-canalization and re-entry devices, considered jointly in the analysis.

Chronic total occlusions (CTOs) are complete blockages of arteries. In the case of a hard plaque, over 50% of the occlusion could consist of calcified tissue. Soft plaques typically consist of cholesterol, macrophages and other cells.
The most common method to cross a CTO is to attempt to pass a guidewire through. In other cases, a specialty hydrophilic guidewire may be used. However, if these guidewire-based methods are not sufficient due to poor visualization and calcified heterogeneous lesions, specialized devices must come into play to enable the subsequent deployment of a stent, PTA balloon or even most atherectomy devices.